key: cord-0848637-ocqk4no3
authors: Siller, A.; Seekircher, L.; Wachter, G. A.; Astl, M.; Tschiderer, L.; Pfeifer, B.; Gaber, M.; Schennach, H.; Willeit, P.
title: Seroprevalence, waning, and correlates of anti-SARS-CoV-2 IgG antibodies in Tyrol, Austria: Large-scale study of 35,193 blood donors conducted between June 2020 and September 2021
date: 2021-12-29
journal: nan
DOI: 10.1101/2021.12.27.21268456
sha: a33806b24bd0569be25fa192fb0a1d39b04a4081
doc_id: 848637
cord_uid: ocqk4no3

Background: There is uncertainty about the seroprevalence of anti-SARS-CoV-2 antibodies in the general population of Austria, and about the extent to which antibodies elicited by vaccination or infection wane over time. Aim: To estimate seroprevalence, waning, and correlates of anti-SARS-CoV-2 IgG antibodies in the Federal State of Tyrol, Austria. Methods: We conducted a seroepidemiological study between June 2020 and September 2021, enrolling blood donors aged 18-70 years across Tyrol, Austria (participation rate 84.0%). We analysed serum samples for antibodies against spike or nucleocapsid proteins of SARS-CoV-2 with Abbott SARS-CoV-2 IgG assays. Results: We performed 47,363 serological tests among 35,193 individuals (median age 43.1 years [IQR: 29.3-53.7], 45.3% women, 10.0% with prior SARS-CoV-2 infection). Seroprevalence increased from 3.4% (95% CI: 2.8-4.2%) in June 2020 to 82.7% (95% CI: 81.4-83.8%) in September 2021, largely due to vaccination. Anti-spike IgG seroprevalence was 99.6% (99.4-99.7%) among fully vaccinated individuals, 90.4% (88.8-91.7%) among unvaccinated with prior infection, and 11.5% (10.8-12.3%) among unvaccinated without known prior infection. Anti-spike IgG levels were reduced by 44.0% (34.9-51.7%) at 5-6 months compared to 0-3 months after infection. In fully vaccinated individuals, they decreased by 31.7% (29.4-33.9%) per month. In multivariable adjusted analyses, both seropositivity among unvaccinated and antibody levels among fully vaccinated individuals were higher at young age (<25 years), higher with a known prior infection, and lower in current smokers. Conclusion: Seroprevalence in Tyrol increased to 82.7% in September 2021, with the bulk of seropositivity stemming from vaccination. Antibody levels substantially and gradually declined after vaccination or infection.

The severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic has been the major public health concern worldwide since December 2019. By the end of November 2021, more than 260 million SARS-CoV-2 infections and 5.2 million related deaths have been reported globally [1] . At the same time, approximately 44% of the world population has been fully vaccinated and 55% has been partially vaccinated against SARS-CoV-2 [1] . As a considerable proportion of populations has already been infected or vaccinated, seroepidemiological studies are important to quantify reliably the seroprevalence of anti-SARS-CoV-2 antibodies at the population level and thereby inform future decision making of governments and health authorities.

There are several studies in different European countries that have assessed the trajectories of anti-SARS-CoV-2 seroprevalence in the general population over time, including studies in blood donors and household samples in Germany [2] and the UK [3, 4] . In Austria, however, previous seroprevalence studies have been restricted to the time before vaccinations against SARS-CoV-2 were licensed [5] [6] [7] and, hence, data on seroprevalence in the vaccination-era is lacking. Moreover, there are scarce data on the rate at which anti-SARS-CoV-2 antibody levels wane after an infection and after vaccination [8, 9] .

To address these uncertainties, we conducted a large-scale seroepidemiological study among blood donors in the Federal State of Tyrol, Austria. Our aims were threefold. First, to reliably determine anti-SARS-CoV-2 IgG seroprevalence for each month between June 2020 and September 2021 and according to the nine districts of Tyrol. Second, to characterise antibody dynamics after SARS-CoV-2 infection and after vaccination. Third, to quantify reliably any differences in anti-SARS-CoV-2 IgG antibodies across relevant population subgroups.

CIs. Serological tests in August and September 2020 were excluded because they were considered as non-representative samples (e.g. 71.4% in Ischgl [12] ). Because the offer to test for anti-SARS-CoV-2 IgG antibodies as part of a blood donation may have mobilised individuals and may thereby have introduced some selection bias, we conducted a sensitivity analysis restricted to individuals with repeat donations since October 2017. Furthermore, we conducted an age-and sex-standardisation using the structure of the total population in Tyrol aged 18-70 years to enhance generalisability of the study estimates [13] . Finally, seroprevalence was also estimated separately for the nine districts of Tyrol andto facilitate interpretationis presented together with (i) cumulative SARS-CoV-2 incidence calculated from public data [14] and (ii) state-wide vaccine coverage provided to the authors by the Corona Operations Centre of the Crises and Disaster Management Team of the Government of Tyrol.

We conducted several subsidiary analyses that focused on the time period with anti-S IgG measurements. First, we quantified seroprevalence in population subgroups defined by vaccination status and prior SARS-CoV-2 infection and tested for differences in antibody levels using linear regression. Second, to investigate differences by population subgroups, we fitted multivariable regression models that included the variables age (<25 vs. ≥25 years), sex (males vs. females), smoking (current vs. never/ex-smokers), body mass index (≥25 vs. <25 kg/m²), prior SARS-CoV-2 infection (yes vs. no) based on complete case analysis. In specific, we used (i) a generalised estimating equation with a logit link function, a binomial distribution family, and an independent variance structure to test for differences in seroprevalence among unvaccinated individuals, and (ii) a linear mixed model with a random intercept to test for differences in antibody levels after full vaccination.

Third, we investigated the stability of anti-S IgG antibody levels after SARS-CoV-2 infection and after vaccination using linear mixed models with random intercepts that incorporated all available repeat measurements. Furthermore, to assess the shape of association with time since SARS-CoV-2 infection, we entered restricted cubic splines with three equidistant knots spread across the range of time since infection into the linear mixed model. Because the distribution of anti-S IgG antibody levels was skewed, we used log-transformed values in all regression models and back-transformed results for presentation. P values ≤0.05 were deemed as statistically significant and all statistical test were twosided. Analyses were carried out with Stata 15.1 and R 4.1.0. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101/2021.12.27.21268456 doi: medRxiv preprint

To assess seroprevalence by vaccination status and prior SARS-CoV-2 infection, we analysed data on 19 ,792 individuals with a measurement of anti-S IgG ( Table 2) Table 3 shows the results of the multivariable regression models we fitted to investigate cross- 

We next quantified the decrease of anti-S IgG antibody levels over time after a person had a SARS-CoV-2 infection or was vaccinated. In an analysis of 1,455 unvaccinated participants with 1,573 repeat measurements (Figure 3) , we observed substantial waning of anti-S IgG antibody levels most notably in the first six months after infection. For instance, compared to the median anti-S IgG levels of 60 BAU/mL (IQR 30-130) at month 0-3 after an infection, anti-S IgG levels were 44.0% lower at month 5-6 (95% CI: 34.9-51.7%) and 58.8% lower at month 10 or later (50.7-65.6%) ( Figure 3B) . Finally, in an analysis of 269 fully vaccinated participants with 2 or more visits resulting in a total of 548 repeat measurements, we observed mean attrition rate in anti-S IgG antibody levels of 31.7% per month (95% CI: 29.4-33.9%). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101/2021.12.27.21268456 doi: medRxiv preprint

The present large-scale study reports on the seroprevalence of anti-SARS-CoV-2 IgG antibodies between summer 2020 and autumn 2021 in 35,193 healthy individuals aged 18-70 years recruited at blood donation events throughout all districts of Tyrol, Austria. In September 2021, seroprevalence was 82.7%, was largely attributable to vaccination rather than past infection, and varied across districts (e.g. 87.6% in the district of Schwaz vs. 74.3% in the district of Lienz). Furthermore, on top of the anticipated differences in seroprevalence and antibody levels by vaccination status and prior SARS-CoV-2 infection, we identified cross-sectional correlations with young age, known prior infection, and smoking that withstood multivariable adjustment. Finally, by incorporating the repeat measurements taken in our longitudinal study, we reliably quantified the progressive waning of antibody levels, occurring after a SARS-CoV-2 infection and after vaccination.

Our study provides much anticipated seroprevalence data that will inform upcoming decisions in the control of the pandemic in Austria. All prior population-based seroepidemiological studies in Austria have been conducted in 2020 and hence before vaccination against SARS-CoV-2 was rolled out to the public. These include a first report from our cohort [5] that revealed a seroprevalence of 3.1% (95% CI: 2.7-3.6%) in June to September 2020 in Tyrol and another study [6] in blood donors in four other Federal States of Austria that showed a seroprevalence of 2.5% (2.2-2.7%) in June to December 2020 in four other Federal States of Austria. Furthermore, in November 2020, a nationwide study involving individuals selected based on household sampling found a seroprevalence of 3.1% (95% CI: 2.2-4.0%) [7] . In contrast to the scarce data in Austria, studies in other European countries have documented the built-up of seroprevalence in the year 2021, e.g. an increase from 3% to 17% by April among German blood donors [2] , an increase from 14% to 61% by May among participants of the English REACT-2 study [3] , and an increase from 8-11% to 91-93% by September across the countries of the United Kingdom [4] . In our study, by September 2021, we found an increase of seroprevalence to 82.7% (95% CI: 81.4-83.8%), which was mainly due to the high vaccination uptake in this age group years), while less than a tenth was attributable to seropositivity induced by infection only. Our study also revealed regional differences across the nine districts of the Tyrol, which were broadly in line with known vaccine coverages and the number of incident SARS-CoV-2 cases documented by the health authorities in the total population. Finally, the age-and sex-distribution in our cohort of blood donors and the general population was well aligned and thereby standardisation of seroprevalence for these demographic variables yielded very similar results.

The remarkably high immunogenicity in fully vaccinated individuals is another important finding, with 99.6% exhibiting anti-S IgG antibodies at the time of blood donation. Partially vaccinated individuals were seropositive only in 79.9% and, when compared to the fully vaccinated group, also hadon averagea more than 10-fold lower absolute level of anti-S IgG. Our data on . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101/2021.12.27.21268456 doi: medRxiv preprint immunogenicity which are largely based on vaccination with BNT162b2 (i.e. 72% of doses in Tyrol by the end of the study [14] , compared to 16% with ChAdOx1-S and 10% with mRNA-1273) are in close agreement with the time trends following receipt of first and second dose vaccination previously reported for mRNA COVID-19 vaccines [15] [16] [17] . Given the limited phenotypic information available in our study, we could not investigate in detail why a small fraction of participants (0.4%) were nonresponders to full vaccination, but different immunocompromising conditions are associated with a lack in immunogenicity [18] . Nevertheless, substantially higher anti-S IgG levels were visible in younger individuals and individuals with prior SARS-CoV-2 infection, while lower anti-S IgG levels were detected among male participants and smokers. Furthermore, by capitalising on the longitudinal data available in our study, we were able to precisely quantify the rate of anti-S IgG antibody waning after vaccination. The overall reduction of 31.7% per month (95% CI: 29.4-33.9%) we observed in our study closely agrees with a previous longitudinal study that investigated waning of antibody levels in 1,647 health care workers after the second dose of a mRNA COVID-19 vaccine [8] , but is slightly less than the 18.3-fold decrease reported in 3,808 health care workers six months after receipt of dose two of the BNT162b2 vaccine [9] , The minimal antibody level however that is required for preventing a SARS-CoV-2 infection or for preventing severe COVID-19 as well as the importance of cell-mediated immunity is still unclear [19, 20] . Nevertheless, our findings support the notion that effectiveness of COVID-19 vaccines is reduced after 4-6 months [21] [22] [23] and that a booster dose is needed to reinstate the protection conferred by the vaccines [19] .

We also conducted a range of analyses focusing on seroprevalence in unvaccinated individuals with or without a prior SARS-CoV-2 infection. Participants with prior SARS-CoV-2 infection were seropositive in 90.4% andconsistent with prior data [16, 17] had a lower antibody level than fully vaccinated participants. A novel contribution of our study is that we were able to characterise the shape of antibody waning after a SARS-CoV-2 infection. In specific, our analyses identified a steep decline of antibody levels in the first six months post-infection (resulting in a 44.0% reduction in total at month 5-6) and a slower decline in the subsequent months. Furthermore, our study revealed that 11.5% of people reporting not to have had SARS-CoV-2 infection actually had been infected unknowingly. The finding in our multivariable adjusted analyses that younger and overweight/obese individuals were more commonly seropositive, while smokers were less commonly seropositive, could stem from (i) differing degrees of exposure and subsequent infection rates or (ii) differing immune responses and antibody dynamics following an infection [5, 24] .

A much discussed concept related to seroprevalence studies is so-called 'herd immunity' or 'population immunity', i.e. a state in which a sufficient proportion of the population is immune to a pathogen to prevent the spread of the pathogen in the entire population including among those that lack immunity. Based on the basic reproduction number of 2.5-3.5 of the virus wild type [25], it was initially estimated that 60-72% immunity is required to reach herd immunity for SARS-CoV-2. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 29, 2021. ;  However, this threshold has been constantly shifted upwards as more infectious SARS-CoV-2 variants [26] or potential immune escape variants have emerged [27] , and as vaccine-induced immunity is not distributed evenly across populations (i.e. differences between countries, difference by age groups, vaccine hesitancy), thereby maintaining high susceptibility to infection in specific groups of individuals [28] . Furthermore, while vaccines against SARS-CoV-2 are highly effective in preventing symptomatic COVID-19, they do not offer complete protection from infection and may not block forward-transmission entirely [29, 30] , thereby undermining a pillar of herd immunity. While there is uncertainty about future developments of the pandemic, in an expert consultation paper, we have previously outlined key determinants and possible courses of the pandemic over the next years [28] .

The study we presented herein has several important strengths and limitations. With data on 35,193 participants with 47,363 analysed samples, our study was adequately powered to reliably quantify time-and region-specific seroprevalence. Furthermore, because a subset of participants donated blood repeatedly, we gained important insight into the dynamics of antibody levels over time. Also, while the eligibility criteria for blood donation restricted our study sample to healthy individuals aged 18-70 years, the age-and sex-structure of our study sample was in close agreement with the general population, thereby supporting the generalisability of our findings to these age groups. Still, when interpreting our seroprevalence estimates, it is crucial to take into account that vaccine coverage among children and adolescents who constitute 17.4% of the population in Tyrol is much lower and therefore seroprevalence across all age groups is expected to be lower. Limitations of our study include (i) the availability of anti-N IgG antibody measurements only up to March 2021 (precluding a clear differentiation of infection-and vaccination-induced seropositivity) and (ii) lack of detailed data on the vaccination regimen (i.e. vaccination dates and vaccine type) because of time constraints at the blood donation centres.

In conclusion, seroprevalence of anti-SARS-CoV-2 antibodies increased from 3.4% in June 2020 to 82.7% in September 2021, with the bulk of seropositivity stemming from vaccination. This study also highlights a substantial gradual decline of antibody levels after vaccination or after SARS-CoV-2 infection. Furthermore, it illustrates that blood donors are well suited as an easily accessible study group for seroepidemiological studies and that they can help to identify local outbreaks of infectious diseases.

The authors report no conflicts of interest in relation to this study. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101/2021.12.27.21268456 doi: medRxiv preprint

The study was supported by the Federal State of Tyrol and the Tirol Kliniken GmbH. The funders had no role in study design, data collection, data analysis, or writing of the report. The corresponding authors had full access to all data in the study and had final responsibility for the decision to submit for publication. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 29, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101/2021.12.27.21268456 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101/2021.12.27.21268456 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101/2021.12.27.21268456 doi: medRxiv preprint

Coronavirus Pandemic (COVID-19)

Serologische Untersuchungen von Blutspenden auf Antikörper gegen SARS-CoV-2 (SeBluCo-Studie)

Vaccine uptake and SARS-CoV-2 antibody prevalence among 207,337 adults during

Antibodies against coronavirus (COVID-19)

Prevalence of SARS-CoV-2 antibodies in healthy blood donors from the state of Tyrol, Austria, in summer 2020

Seroprevalence of anti-SARS-CoV-2 total antibody is higher in younger Austrian blood donors

Mehr als die Hälfte der SARS-CoV-2-Infektionen kurz vor dem zweiten Lockdown sind behördlich nicht erfasst

Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

data.gv.at -Open Data Österreich. Katalog COVID-19: Zeitliche Darstellung von Daten zu Covid19-Fällen je Bezirk

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines. medRxiv

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study

Are COVID-19 Vaccine Boosters Needed? The Science behind Boosters

SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

Covid-19 Vaccine

Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at

Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa

A look into the future of the COVID-19 pandemic in Europe: an expert consultation

thereby reflecting infections that occurred up to this period. Results for earlier periods are provided in Supplementary Figure S1. b Individuals were classified as fully vaccinated if they had received two doses of the BNT162b2, mRNA-1273, or ChAdOx1-S vaccine or one dose of the Ad26.COV2.S vaccine or they had recovered from COVID-19 and had received one dose of any vaccine

The authors thank all employees of the infection serology laboratory of the Central Institute for Blood Transfusion and Immunology, Tirol Kliniken GmbH, namely Barbara Schennach, Elfriede Lanser, Julia Penz, Andrea Schiestl, Sabrina Schmid, and Michaela Szabo. We also thank Katharina Lerchster, Barbara Schlögl, and Helga Egger for processing of questionnaire data and all employees of the blood